JPH10512143A - ヒトpak65 - Google Patents
ヒトpak65Info
- Publication number
- JPH10512143A JPH10512143A JP8521283A JP52128396A JPH10512143A JP H10512143 A JPH10512143 A JP H10512143A JP 8521283 A JP8521283 A JP 8521283A JP 52128396 A JP52128396 A JP 52128396A JP H10512143 A JPH10512143 A JP H10512143A
- Authority
- JP
- Japan
- Prior art keywords
- hpak65
- protein
- nucleic acid
- sequence
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.hPAK65タンパク質またはそれから誘導された少なくとも25アミノ 酸の断片をコードする配列を含んでなる、精製、単離された核酸。 2.核酸がhPAK65のcDNA配列を含んでなる、請求項1に記載の核酸 。 3.核酸がhPAK65をコードする配列に対して相補的な配列である、請求 項1に記載の核酸。 4.核酸がhPAK65をコードする核酸配列またはその相補的配列から本質 的に成る、請求項1に記載の核酸。 5.hPAK65をコードする核酸配列が第2A図におけるそれに対応する、 請求項1に記載の核酸。 6.hPAK65が第2A図におけるアミノ酸配列(配列番号:2)を有する 、請求項1に記載の核酸。 7.cDNAが第2A図における核酸配列(配列番号:1)を有する、請求項 2に記載の核酸。 8.hPAK65をコードする核酸配列が天然に存在する、請求項1に記載の 核酸。 9.核酸配列が高いストリンジェンシイの条件下にhPAK65核酸配列に対 してハイブリダイゼーション可能である、請求項1に記載の核酸。 10.核酸配列が第2A図の核酸配列をコードするhPAK65に対して少な くとも95%相同である、請求項1に記載の核酸。 11.第2A図のhPAK65アミノ酸配列49〜113から本質的に成るア ミノ酸配列をコードする核酸配列を含んでなる、請求項1に記載の核酸。 12.hPAK65が少なくとも1つの保存的アミノ酸置換を有する、請求項 1に記載の核酸。 13.請求項1に記載の核酸を含んでなるベクター。 14.請求項1に記載の核酸で形質転換された宿主細胞。 15.hPAK65核酸配列が(a)請求項1に記載のhPAK65配列の発 現を指令することができる発現制御配列に作用的に関連しているか、または(b )必要に応じて中断されており、hPAK65をコードし、そしてhPAK65 をコードする配列に対して5’または3’の少なくとも1つの非野生型DNA配 列により隣接されている、請求項14に記載の宿主細胞。 16.構成的セリンキナーゼ活性を有するhPAK65ポリペプチドを含んで なる、請求項14に記載の宿主細胞。 17.請求項1に記載の核酸によりコードされるペプチドを含んでなるポリペ プチド。 18.hPAK65からの少なくとも5アミノ酸配列を含んでなり、そしてh PAK65に対するp21タンパク質の結合を阻害する能力を有するペプチドま たはペプチド模倣物。 19.配列番号:2のアミノ酸49〜113からのアミノ酸配列を含んでなる ポリペプチド。 20.適当な培地中で請求項14に記載の宿主細胞を培養し、そしてhPAK 65を単離することを含んでなる、hPAK65を生産する方法。 21.請求項20に記載の方法により生産されたポリペプチド。 22.hPAK65またはセリンキナーゼ活性を有するその断片を含んでなる 、実質的に精製されたペプチド、実質的に精製されたhPAK65キナーゼ基質 、およびγ−32P−ATPを含んでなる反応混合物に化合物を投与し、そして 前記化合物がそれを欠如する対照反応に比較してhPAK65基質のリン酸化 を阻害する程度を決定する、 ことを含んでなる、hPAK65キナーゼ活性を阻害する化合物を同定する方法 。 23.hPAK65キナーゼ阻害アッセイにおいて決定して、hPAK65キ ナーゼ活性を阻害する能力を有する化合物と、hPAK65キナーゼを含有する 組成物とを接触させる、ことを含んでなる、hPAK65キナーゼを阻害する方 法。 24.前記組成物が哺乳動物の体液を含んでなる、請求項23に記載の方法。 25.hPAK65キナーゼ阻害アッセイにおいて決定して、hPAK65キ ナーゼ活性を阻害する能力を有する化合物と、薬学上許容される担体とを含んで なる、哺乳動物におけるhPAK65キナーゼ依存性疾患を抑制する医薬組成物 。 26.hPAK65キナーゼ依存性疾患に罹った哺乳動物に、hPAK65キ ナーゼ阻害アッセイにおいて決定してhPAK65キナーゼ活性を阻害する能力 を有する化合物を、hPAK65キナーゼ依存性疾患抑制量において、投与する ことを含んでなる、hPAK65キナーゼ依存性疾患を抑制する方法。 27.ある物質を実質的に精製されたp21タンパク質と混合して、hPAK 65rac1結合活性を有するhPAK65またはその断片を含んでなる実質的 に精製されたペプチドを含む反応混合物に投与し、そして 前記物質が、前記物質を欠如する対照反応に比較して、前記結合を阻害する程 度を決定する、 hPAK65p21タンパク質の結合活性を阻害する物質を同定する方法。 28.hPAK65断片がGST−PAKette融合タンパク質である、請 求項27に記載の方法。 29.hPAK65p21タンパク質結合阻害アッセイにおいて決定して、h PAK65p21タンパク質の結合活性を阻害する能力を有する化合物と、hP AK65ポリペプチドを含有する組成物とを接触させることを含んでなる、hP AK65p21タンパク質の結合活性を阻害する方法。 30.p21タンパク質結合活性を有するhPAK65ポリペプチドと、p2 1タンパク質ポリペプチドと、ある物質とを含む、異種二量体化アッセイを行い 、そして 前記物質が異種二量体化を変調するかどうかを決定する、 hPAK65調節物質を同定する方法。 31.異種二量体化アッセイが試験管内結合反応を含んでなる、請求項30に 記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/369,780 | 1995-01-06 | ||
US08/369,780 US5518911A (en) | 1995-01-06 | 1995-01-06 | Human PAK65 |
PCT/US1996/000487 WO1996020948A1 (en) | 1995-01-06 | 1996-01-05 | Human pak65 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006066815A Division JP2006230410A (ja) | 1995-01-06 | 2006-03-10 | ヒトpak65 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10512143A true JPH10512143A (ja) | 1998-11-24 |
Family
ID=23456883
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8521283A Pending JPH10512143A (ja) | 1995-01-06 | 1996-01-05 | ヒトpak65 |
JP2006066815A Pending JP2006230410A (ja) | 1995-01-06 | 2006-03-10 | ヒトpak65 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006066815A Pending JP2006230410A (ja) | 1995-01-06 | 2006-03-10 | ヒトpak65 |
Country Status (11)
Country | Link |
---|---|
US (5) | US5518911A (ja) |
EP (1) | EP0802921B1 (ja) |
JP (2) | JPH10512143A (ja) |
AT (1) | ATE414763T1 (ja) |
AU (1) | AU702308B2 (ja) |
CA (1) | CA2209426C (ja) |
DE (1) | DE69637754D1 (ja) |
DK (1) | DK0802921T3 (ja) |
ES (1) | ES2319583T3 (ja) |
PT (1) | PT802921E (ja) |
WO (1) | WO1996020948A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007537134A (ja) * | 2003-07-18 | 2007-12-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 関節病を治療するためのpak阻害剤の使用 |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5518911A (en) * | 1995-01-06 | 1996-05-21 | Onyx Pharmaceuticals, Inc. | Human PAK65 |
US5863532A (en) | 1996-03-14 | 1999-01-26 | The Regents Of The University Of California | Compositions and methods comprising cytostatic protein kinase |
WO1998007830A2 (en) | 1996-08-22 | 1998-02-26 | The Institute For Genomic Research | COMPLETE GENOME SEQUENCE OF THE METHANOGENIC ARCHAEON, $i(METHANOCOCCUS JANNASCHII) |
DE69827179T2 (de) * | 1997-02-19 | 2005-03-10 | Arpida Ag | Verfahren zur Behandlung von mikrobiellen Infektionen mittels Entkupplung des Phosphotransferase-Systems und dazu geeignete Wirkstoffe |
US6777176B1 (en) * | 1997-02-19 | 2004-08-17 | Arpida Ag | Target system |
US6069229A (en) | 1997-03-07 | 2000-05-30 | Schering Corporation | Mammalian proteinases; oxidoreductases; related reagents |
US6489137B2 (en) | 1997-06-11 | 2002-12-03 | Chiron Corporation | Detection of loss of the wild-type huBUB1 gene |
US6410312B1 (en) | 1997-12-19 | 2002-06-25 | Chiron Corporation | huBUB3 gene involved in human cancers |
US6227658B1 (en) | 1997-06-23 | 2001-05-08 | Kabushiki Kaisha Toshiba | Apparatus and method for forming thin film using ink-jet mechanism |
EP0889127A1 (en) * | 1997-07-01 | 1999-01-07 | Smithkline Beecham Corporation | Serine/threonine protein kinase (H-SGK2) |
US6218109B1 (en) * | 1997-09-05 | 2001-04-17 | Baylor College Of Medicine | Mammalian checkpoint genes and proteins |
US6524833B1 (en) | 1997-12-09 | 2003-02-25 | Children's Medical Center Corporation | Two sterile-20 kinase-like proteins and methods of use thereof |
JPH11232291A (ja) * | 1998-02-16 | 1999-08-27 | Seibutsu Bunshi Kogaku Kenkyusho:Kk | 蛋白質立体構造データベース検索方法 |
US6013500A (en) | 1998-05-21 | 2000-01-11 | The Trustees Of Columbia University In The City Of New York | PAK4, a novel gene encoding a serine/threonine kinase |
US6500653B1 (en) | 1998-08-07 | 2002-12-31 | Onyx Pharmaceuticals, Inc. | Nucleic acids and polypeptides which resemble RHO and which interact with cell signaling pathways and proteins |
US6383734B1 (en) | 1998-09-30 | 2002-05-07 | Advanced Research And Technology Institute, Inc. | Method to determine inhibition of PAK3 activation of Raf-1 |
US6013455A (en) * | 1998-10-15 | 2000-01-11 | Incyte Pharmaceuticals, Inc. | Protein kinase homologs |
EP1088898A1 (en) * | 1999-09-16 | 2001-04-04 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | A new assay to detect substances useful for the therapy of cancer and infectious diseases |
CN1315567A (zh) * | 2000-03-28 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人atp依赖的丝氨酸蛋白水解酶10和编码这种多肽的多核苷酸 |
CN1315566A (zh) * | 2000-03-28 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人atp依赖的丝氨酸蛋白水解酶52和编码这种多肽的多核苷酸 |
CN1315568A (zh) * | 2000-03-28 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人atp依赖的丝氨酸蛋白水解酶11.4和编码这种多肽的多核苷酸 |
CN1315571A (zh) * | 2000-03-29 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人atp依赖的丝氨酸蛋白水解酶9.8和编码这种多肽的多核苷酸 |
CN1315573A (zh) * | 2000-03-29 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人atp依赖的丝氨酸蛋白水解酶11和编码这种多肽的多核苷酸 |
CN1315572A (zh) * | 2000-03-29 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人atp依赖的丝氨酸蛋白水解酶12和编码这种多肽的多核苷酸 |
CN1315570A (zh) * | 2000-03-29 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人atp依赖的丝氨酸蛋白水解酶16和编码这种多肽的多核苷酸 |
CN1315569A (zh) * | 2000-03-29 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人atp依赖的丝氨酸蛋白水解酶11.3和编码这种多肽的多核苷酸 |
CN1321768A (zh) * | 2000-04-29 | 2001-11-14 | 上海博德基因开发有限公司 | 一种新的多肽——人atp依赖的丝氨酸蛋白水解酶21和编码这种多肽的多核苷酸 |
CN1322834A (zh) * | 2000-05-09 | 2001-11-21 | 上海博德基因开发有限公司 | 一种新的多肽——人atp依赖的丝氨酸蛋白水解酶9.2和编码这种多肽的多核苷酸 |
AU2001271614B2 (en) | 2000-07-03 | 2007-05-31 | Catalent Pharma Solutions, Llc | Host cells containing multiple integrating vectors |
AU7025201A (en) * | 2000-07-03 | 2002-01-14 | Gala Design Inc | Expression vectors |
FR2812945B1 (fr) * | 2000-08-10 | 2002-10-04 | Aventis Pharma Sa | Utilisation de la proteine grf1 et cellules exprimant la proteine grf1 pour le criblage de molecules |
ATE378400T1 (de) * | 2001-02-14 | 2007-11-15 | Sysmex Corp | Verfahren zur bestimmung der aktivität des zellzyklus-regulationsfaktors und verfahren zur diagnose von krebs unter verwendung desselben |
US20030134353A1 (en) * | 2001-03-08 | 2003-07-17 | Bioteknologisk Institut | Recombinant dimorphic fungal cell |
AU2002316631A1 (en) * | 2001-07-12 | 2003-01-29 | Exelixis, Inc. | Ube2s as modifiers of the p21 pathway and methods of use |
US7514207B2 (en) * | 2001-08-13 | 2009-04-07 | Massachusetts Institute Of Technology | Methods of screening for compounds that decrease phosphorylation of merlin and may be useful in cancer treatment |
JP2005518198A (ja) | 2001-12-28 | 2005-06-23 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | Pak5関連の組成物及び方法 |
JP3960083B2 (ja) * | 2002-03-06 | 2007-08-15 | セイコーエプソン株式会社 | ヘッド駆動装置及び方法、液滴吐出装置、ヘッド駆動プログラム、並びにデバイス製造方法及びデバイス |
US7384738B2 (en) * | 2002-03-28 | 2008-06-10 | Bremel Robert D | Retrovirus-based genomic screening |
US20040038304A1 (en) * | 2002-03-28 | 2004-02-26 | Gala Design, Inc. | Antibody libraries |
US20040009935A1 (en) * | 2002-07-03 | 2004-01-15 | Isis Pharmaceuticals Inc. | Antisense modulation of p21-activated kinase 2 expression |
WO2004014947A1 (en) * | 2002-08-06 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Method for isolating an intestinal cholesterol binding protein |
US20040248323A1 (en) * | 2003-06-09 | 2004-12-09 | Protometrix, Inc. | Methods for conducting assays for enzyme activity on protein microarrays |
US7364887B2 (en) * | 2003-07-18 | 2008-04-29 | Sanofi-Aventis Deutschland Gmbh | Use of PAK inhibitor for the treatment of a joint disease |
US20050221429A1 (en) * | 2004-01-16 | 2005-10-06 | Cardinal Health Pts, Llc | Host cells containing multiple integrating vectors comprising an amplifiable marker |
WO2005094876A1 (en) * | 2004-03-04 | 2005-10-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with p21 (cdkn1a)-activated kinase 2 (pak2) |
US20090111786A1 (en) * | 2004-12-03 | 2009-04-30 | Glass Christopher K | Compounds that Prevent Macrophage Apoptosis and Uses Thereof |
WO2009051825A1 (en) * | 2007-10-17 | 2009-04-23 | University Of Miami | Use of rac1 inhibitors to treat kaposi's sarcoma |
US7998688B2 (en) * | 2008-03-07 | 2011-08-16 | OSI Pharmaceuticals, LLC | Inhibition of EMT induction in tumor cells by anti-cancer agents |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5518911A (en) * | 1995-01-06 | 1996-05-21 | Onyx Pharmaceuticals, Inc. | Human PAK65 |
US5863532A (en) * | 1996-03-14 | 1999-01-26 | The Regents Of The University Of California | Compositions and methods comprising cytostatic protein kinase |
-
1995
- 1995-01-06 US US08/369,780 patent/US5518911A/en not_active Expired - Lifetime
- 1995-06-07 US US08/475,682 patent/US5605825A/en not_active Expired - Lifetime
-
1996
- 1996-01-05 EP EP96903482A patent/EP0802921B1/en not_active Expired - Lifetime
- 1996-01-05 AU AU47560/96A patent/AU702308B2/en not_active Ceased
- 1996-01-05 DK DK96903482T patent/DK0802921T3/da active
- 1996-01-05 CA CA002209426A patent/CA2209426C/en not_active Expired - Fee Related
- 1996-01-05 ES ES96903482T patent/ES2319583T3/es not_active Expired - Lifetime
- 1996-01-05 WO PCT/US1996/000487 patent/WO1996020948A1/en active Application Filing
- 1996-01-05 PT PT96903482T patent/PT802921E/pt unknown
- 1996-01-05 DE DE69637754T patent/DE69637754D1/de not_active Expired - Lifetime
- 1996-01-05 AT AT96903482T patent/ATE414763T1/de active
- 1996-01-05 JP JP8521283A patent/JPH10512143A/ja active Pending
- 1996-04-22 US US08/636,036 patent/US5698445A/en not_active Expired - Lifetime
-
1997
- 1997-01-10 US US08/780,833 patent/US5698428A/en not_active Expired - Lifetime
- 1997-08-22 US US08/918,509 patent/US6013464A/en not_active Expired - Lifetime
-
2006
- 2006-03-10 JP JP2006066815A patent/JP2006230410A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007537134A (ja) * | 2003-07-18 | 2007-12-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 関節病を治療するためのpak阻害剤の使用 |
Also Published As
Publication number | Publication date |
---|---|
EP0802921A1 (en) | 1997-10-29 |
CA2209426C (en) | 2008-10-07 |
ES2319583T3 (es) | 2009-05-08 |
AU702308B2 (en) | 1999-02-18 |
US5698445A (en) | 1997-12-16 |
WO1996020948A1 (en) | 1996-07-11 |
EP0802921B1 (en) | 2008-11-19 |
US5605825A (en) | 1997-02-25 |
US6013464A (en) | 2000-01-11 |
EP0802921A4 (en) | 2000-03-29 |
US5518911A (en) | 1996-05-21 |
CA2209426A1 (en) | 1996-07-11 |
PT802921E (pt) | 2009-02-25 |
ATE414763T1 (de) | 2008-12-15 |
AU4756096A (en) | 1996-07-24 |
DE69637754D1 (de) | 2009-01-02 |
DK0802921T3 (da) | 2009-03-16 |
JP2006230410A (ja) | 2006-09-07 |
US5698428A (en) | 1997-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10512143A (ja) | ヒトpak65 | |
Narumiya | The small GTPase Rho: cellular functions and signal transduction | |
US20030064439A1 (en) | Novel nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, ATPase molecules, acyltransferase molecules, pyridoxal-phosphate dependant enzyme molecules and uses therefor | |
AU736316B2 (en) | Mitogen-activated protein kinase p38-2 and methods of use therefor | |
CA2433795A1 (en) | Methods to identify compounds useful for the treatment of proliferative and differentiative disorders | |
US6048706A (en) | Human PAK65 | |
EP1263939B1 (en) | 18477, a human protein kinase and uses therefor | |
US6812014B2 (en) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins and uses thereof | |
US6383791B1 (en) | Molecules of the HKID-1-related protein family and uses thereof | |
US6958238B2 (en) | Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof | |
US7049119B2 (en) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof | |
JP2005504830A (ja) | Hkid−1関連タンパク質ファミリーの新規な分子およびその使用 | |
US6946276B2 (en) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof | |
US6365372B1 (en) | SNF2 related CBP activator protein (SRCAP) | |
US6716604B2 (en) | Nucleic acid molecules encoding a subunit of a human calcium/calmodulin-dependent protein kinase | |
US6340584B1 (en) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof | |
US6686187B2 (en) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof | |
WO2003047611A2 (en) | Ptp10d, tec and edtp involved in triglycerid-metabolism | |
US6653116B2 (en) | Isolated human kinase proteins | |
US20020168742A1 (en) | 59079 and 12599, protein kinase family members and uses therefor | |
US20040048305A1 (en) | 14171 Protein kinase, a novel human protein kinase and uses thereof | |
US20050244833A1 (en) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof | |
CA2443181A1 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
CA2439800A1 (en) | Isolated human kinase proteins, their encoding nucleic acid molecules, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050913 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051207 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060310 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060829 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061128 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070226 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080916 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081215 |